Atria Investments Inc Has $103,000 Holdings in Fortress Biotech, Inc. (NASDAQ:FBIO)

Atria Investments Inc raised its holdings in shares of Fortress Biotech, Inc. (NASDAQ:FBIO) by 58.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,484 shares of the biopharmaceutical company’s stock after acquiring an additional 26,351 shares during the quarter. Atria Investments Inc’s holdings in Fortress Biotech were worth $103,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in FBIO. Virtu Financial LLC purchased a new position in Fortress Biotech during the first quarter valued at approximately $31,000. 180 Wealth Advisors LLC acquired a new stake in shares of Fortress Biotech during the 2nd quarter valued at $107,000. B. Riley Wealth Advisors Inc. purchased a new position in shares of Fortress Biotech during the 2nd quarter valued at $207,000. PVG Asset Management Corp purchased a new position in shares of Fortress Biotech during the 2nd quarter valued at $266,000. Finally, Shikiar Asset Management Inc. increased its stake in shares of Fortress Biotech by 4.4% in the third quarter. Shikiar Asset Management Inc. now owns 235,969 shares of the biopharmaceutical company’s stock worth $342,000 after acquiring an additional 10,000 shares during the last quarter. Institutional investors and hedge funds own 96.51% of the company’s stock.

Fortress Biotech Price Performance

FBIO opened at $1.61 on Monday. The company’s 50 day simple moving average is $1.68 and its 200-day simple moving average is $1.83. Fortress Biotech, Inc. has a one year low of $1.36 and a one year high of $4.43. The stock has a market capitalization of $44.44 million, a P/E ratio of -0.53 and a beta of 1.75.

Insider Buying and Selling at Fortress Biotech

In other Fortress Biotech news, CEO Lindsay A. Md Rosenwald acquired 763,359 shares of the business’s stock in a transaction dated Monday, September 23rd. The shares were acquired at an average price of $1.84 per share, for a total transaction of $1,404,580.56. Following the acquisition, the chief executive officer now directly owns 3,657,264 shares of the company’s stock, valued at approximately $6,729,365.76. This trade represents a 26.38 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 33.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on FBIO shares. StockNews.com cut Fortress Biotech from a “hold” rating to a “sell” rating in a research note on Friday, November 15th. HC Wainwright lifted their price objective on Fortress Biotech from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Monday, November 18th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $13.67.

About Fortress Biotech

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.